Global investment firm EQT recently signed a definitive agreement to acquire the specialized biosurgery business from Corza Medical. This strategic corporate transaction centers entirely around TachoSil. Specifically, this flagship product functions as a dual-action active biologic patch. The innovative patch effectively controls bleeding and seals human tissue during complex operations.
Consequently, this milestone transaction transitions the biosurgery division into an independent standalone entity. Following the official closing, former Johnson & Johnson executive Sheri McCoy will assume the role of Board Chair.
Ethan Waxman, Partner at EQT, said: “TachoSil has a unique clinical value proposition that improves patient outcomes across critical surgical procedures around the world, and is backed by strong physician preference and extensive clinical evidence. We are deeply impressed by the dedication of the Corza Biosurgery team and look forward to partnering with them to expand access globally, invest in growth, and further strengthen the Company’s position as a leading biosurgery platform.”
“We are excited to partner with EQT during a pivotal moment for TachoSil,” said Thierry Leclercq, President of Corza Biosurgery. “EQT’s healthcare expertise, operational resources, and commitment to long-term growth align perfectly with our vision to expand access to TachoSil globally and advance innovation.”
Driving Global Surgical Innovation
The company that is being divested employs about 400 people around the world. A very advanced manufacturing facility is operated by a specialized medical team in Linz, Austria. This unique patch is used today by leading surgeons in 50 countries. It is a reliable aid in cardiovascular, neuro, hepatic, and thoracic procedures.
Also, the global increase in surgical volumes is driving commercial demand for advanced medical technologies. The increase comes from an aging world population and more chronic illnesses. Thus, the novel patch consistently shortens the operating times and hastens the patient’s recovery overall.
Future Growth and Corporate Strategy
Moving forward, EQT plans to invest heavy financial resources into global commercial capabilities. The private firm will explicitly target aggressive market growth across the United States. Additionally, management will focus on structural partnerships and complementary corporate acquisitions.
Meanwhile, the parent company will continue investing across its remaining core surgical technology portfolios. These specialized areas include wound closure, ophthalmology, and biomedical textiles. The entire transaction remains subject to customary closing conditions and regulatory approvals. Both parties expect the deal to officially close during the final quarter of 2026. This divestiture ultimately creates an exciting new growth chapter for Corza Medical.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: PRNewswire.com
